Sorry this took so long. This was partly due to my schedule and partly because we’ve been in a process of transitioning to PrescribeToPrevent. You can thank those unnamed persons who reached out to me asking when the next installment was coming for avoiding a much greater delay!
108 articles in four months. The fentanyl ones are all at the end in a special section, as are the injection facility ones. The rest you will have to parse through. Okay, that’s it – I feel myself turning into a pumpkin.
Horton M, McDonald R, Green TC, Nielsen S, Strang J, Degenhardt L, Larney S.
Int J Drug Policy. 2017 May 30;46:7-16. doi: 10.1016/j.drugpo.2017.05.015. [Epub ahead of print]
Comment: Naloxone pre-release is totally doable, but outcome studies have run into some challenges.
Chavoustie S, Frost M, Snyder O, Owen J, Darwish M, Dammerman R, Sanjurjo V.
Expert Rev Clin Pharmacol. 2017 Jun 2. doi: 10.1080/17512433.2017.1336434. [Epub ahead of print]
Comment: Looking forward to this. It should overcome a lot of the misinformed resistance.
Jiang R, Lee I, Lee TA, Pickard AS.
PLoS One. 2017 May 30;12(5):e0177323. doi: 10.1371/journal.pone.0177323. eCollection 2017.
Comment: I haven’t read this in depth, but find it a bit disturbing. It always seems a bit off in economic models when you “charge” people for incarcerating them.
Kozlenkov A, Jaffe AE, Timashpolsky A, Apontes P, Rudchenko S, Barbu M, Byne W, Hurd YL, Horvath S, Dracheva S.
Genes (Basel). 2017 May 30;8(6). pii: E152. doi: 10.3390/genes8060152.
Comment: Possible heroin-associated changes in the prefrontal cortex.
Chang G, Davids M, Kershaw A.
J Addict Dis. 2017 May 26:0. doi: 10.1080/10550887.2017.1333331. [Epub ahead of print]
Comment: 89% of outpatient and 63% of inpatient veterans accepted take-home naloxone.
Piper BJ, Desrosiers CE, Fisher HC, McCall KL, Nichols SD.
Pharmacotherapy. 2017 May 19. doi: 10.1002/phar.1952. [Epub ahead of print]
Comment: A registry of drug arrests including type of drug.
Roxburgh A, Darke S, Salmon AM, Dobbins T, Jauncey M.
Drug Alcohol Depend. 2017 May 17;176:126-132. doi: 10.1016/j.drugalcdep.2017.02.027. [Epub ahead of print]
Comment: Great data. 12.7 overdose events per 1,000 heroin injections; 4.1 oxycodone overdoses per 1,000 injections. Another confirmation that injecting prescribed opioids is safer than heroin / street drugs, and thus possibly explaining at least part of the increase in overdose death while we pull back on opioid prescribing.
Avetian GK, Fiuty P, Mazzella S, Koppa D, Heye V, Hebbar P.
Curr Med Res Opin. 2017 May 23:1-9. doi: 10.1080/03007995.2017.1334637. [Epub ahead of print]
Comment: Some good initial field data on the 4mg nasal spray. We were worried about precipitated withdrawal, but the results seem to be pretty similar to the other doses. 98.8% survived and 2 of the 3 deaths were thought to be already dead when naloxone was administered (there was no further info for the third case). 14% had withdrawal, 10% had retching/vomiting type symptoms, and 9% were angry. Interestingly, given the “high” dose and exposure of this product, a second dose was used 33% of the time, with >=3 doses in 2.4% of cases. As we know, it is difficult to wait for naloxone to start to work, and many of the second doses are administered in a panic rather than due to lack of effect of the first dose.
Madah-Amiri D, Clausen T, Lobmaier P.
Drug Alcohol Depend. 2017 Apr 1;173:17-23. doi: 10.1016/j.drugalcdep.2016.12.013. Epub 2017 Jan 28.
Comment: Government-supported program gets the product out fast.
Jones CM, Christensen A, Gladden RM.
Drug Alcohol Depend. 2017 May 16;176:89-95. doi: 10.1016/j.drugalcdep.2017.03.011. [Epub ahead of print]
Comment: When you look at the years in Figure 1, once again the biggest change centers around 2010, a key year in all of the opioid trend graphs.
Sharma A, Kelly SM, Mitchell SG, Gryczynski J, O’Grady KE, Schwartz RP.
Curr Psychiatry Rep. 2017 Jun;19(6):35. doi: 10.1007/s11920-017-0783-9. Review.
Comment: Financial, regulatory, geographic, attitudinal, and logistic.
Boyd S, Murray D; SNAP, MacPherson D.
Harm Reduct J. 2017 May 18;14(1):27. doi: 10.1186/s12954-017-0152-3.
Comment: Some powerful activism in Vancouver.
Oviedo-Joekes E, Brissette S, MacDonald S, Guh D, Marchand K, Jutha S, Harrison S, Janmohamed A, Zhang DZ, Anis AH, Krausz M, Marsh DC, Schechter MT.
Drug Alcohol Depend. 2017 May 10;176:55-62. doi: 10.1016/j.drugalcdep.2017.02.021. [Epub ahead of print]
Comment: Generally, in a chronic disease that requires ongoing management and can be extremely morbid, we accept with open arms any treatment that has at least some benefit.
Elzey MJ, Barden SM, Edwards ES.
Pain Physician. 2016 May;19(4):215-28. Review.
Comment: We need to study non-fatal overdose more.
Gufford BT, Ainslie GR, White JR Jr, Layton ME, Padowski JM, Pollack GM, Paine MF.
Clin Transl Sci. 2017 May 15. doi: 10.1111/cts.12473. [Epub ahead of print]
Comment: Interesting data comparing the products; overall 2mg IN and 2mg IM naloxone were pretty similar.
Lyndon A, Audrey S, Wells C, Burnell ES, Ingle S, Hill R, Hickman M, Henderson G.
Addiction. 2017 May 10. doi: 10.1111/add.13843. [Epub ahead of print]
Comment: Interesting. Initially I suspected that the association of increased prescribing of gabapentins and increased opioid overdose mortality was a nature of the growing population of opioid dependent persons, but the authors present some interview data and animal data suggesting that these agents lessen the tolerance to the respiratory depressive effects of opioids. Is this yet another combination we should try to avoid clinically? We are running out of options.
Winograd RP, Davis CS, Niculete M, Oliva E, Martielli RP.
Subst Abus. 2017 Apr-Jun;38(2):135-140. doi: 10.1080/08897077.2017.1303424.
Comment: I find it so weird that a physician would say that prescribing naloxone would increase opioid use. I doubt any would say the same about prescribing or recommending insulin, glucagon, epinephrine pens, or fire extinguishers.
Faul M, Lurie P, Kinsman JM, Dailey MW, Crabaugh C, Sasser SM.
Prehosp Emerg Care. 2017 May 8:1-8. doi: 10.1080/10903127.2017.1315203. [Epub ahead of print]
Comment: Pretty good analysis.
Stein MD, Anderson BJ, Kenney SR, Bailey GL.
J Subst Abuse Treat. 2017 Jun;77:67-71. doi: 10.1016/j.jsat.2017.03.002. Epub 2017 Mar 9.
Comment: Benzo users generally know that they are risky.
Jordan AE, Blackburn NA, Des Jarlais DC, Hagan H.
J Subst Abuse Treat. 2017 Jun;77:31-37. doi: 10.1016/j.jsat.2017.03.007. Epub 2017 Mar 12.
Comment: Increased through the 2000s.
Hendley TM, Hersh EV, Moore PA, Stahl B, Saraghi M.
Gen Dent. 2017 May-Jun;65(3):18-21. No abstract available.
Comment: Can’t access.
Best D, Man LH, Gossop M, Noble A, Strang J.
Drug Alcohol Rev. 2000 Dec;19(4):407-412. doi: 10.1080/713659420.
Comment: Drug users are interested in overdose prevention…
Ann Intern Med. 2017 May 2;166(9):687. doi: 10.7326/M17-0652. No abstract available.
Comment: This is a small correction in one of the appendix tables from the Coffin cost-effectiveness paper. There was an error in Appendix Table 3, where the total number of overdose events was overcounted. The correction is in the online table only:
Pricolo A, Nielsen S.
Drug Alcohol Rev. 2017 Apr 27. doi: 10.1111/dar.12547. [Epub ahead of print]
Comment: Overcomes the standing order barrier that the U.S. has.
Saulle R, Vecchi S, Gowing L.
Cochrane Database Syst Rev. 2017 Apr 27;4:CD011983. doi: 10.1002/14651858.CD011983.pub2. Review.
Comment: Not much data comparing supervised to unsupervised dosing.
Vanky E, Hellmundt L, Bondesson U, Eksborg S, Lundeberg S.
Acta Anaesthesiol Scand. 2017 Jul;61(6):636-640. doi: 10.1111/aas.12898. Epub 2017 Apr 25.
Comment: Using a 0.4mg/mL formulation intranasally (which nobody uses), uptake was fast and concentration highly variable.
Wiessing L, Ferri M, Běláčková V, Carrieri P, Friedman SR, Folch C, Dolan K, Galvin B, Vickerman P, Lazarus JV, Mravčík V, Kretzschmar M, Sypsa V, Sarasa-Renedo A, Uusküla A, Paraskevis D, Mendão L, Rossi D, van Gelder N, Mitcheson L, Paoli L, Gomez CD, Milhet M, Dascalu N, Knight J, Hay G, Kalamara E, Simon R; EUBEST working group, Comiskey C, Rossi C, Griffiths P.
Harm Reduct J. 2017 Apr 22;14(1):19. doi: 10.1186/s12954-017-0141-6.
Comment: Really cool set of best practice indicators.
Mundin G, McDonald R, Smith K, Harris S, Strang J.
Addiction. 2017 Apr 21. doi: 10.1111/add.13849. [Epub ahead of print]
Comment: Concentrated nasal naloxone pk data.
Bagley SM, Forman LS, Ruiz S, Cranston K, Walley AY.
Drug Alcohol Rev. 2017 Apr 20. doi: 10.1111/dar.12551. [Epub ahead of print]
Comment: Good experience.
Pan A, Zakowski M.
Clin Obstet Gynecol. 2017 Jun;60(2):447-458. doi: 10.1097/GRF.0000000000000288.
Comment: As above.
Olsen A, McDonald D, Lenton S, Dietze PM.
Drug Alcohol Rev. 2017 Apr 18. doi: 10.1111/dar.12523. [Epub ahead of print]
Comment: There’s more than Bradford Hill criteria supporting naloxone. Very little we do in medicine has RCT data.
Nadpara PA, Joyce AR, Murrelle EL, Carroll NW, Carroll NV, Barnard M, Zedler BK.
Pain Med. 2017 Apr 13. doi: 10.1093/pm/pnx038. [Epub ahead of print]
Comment: Risk factors were similar in the two populations, including substance use disorder, depression, other mental health disorders, organ dysfunction, higher doses, fentanyl/morphine/methadone, and other psychoactive medications.
Stopka TJ, Donahue A, Hutcheson M, Green TC.
J Am Pharm Assoc (2003). 2017 Mar – Apr;57(2S):S34-S44. doi: 10.1016/j.japh.2016.12.077. Epub 2017 Feb 8.
Comment: 45% of surveyed pharmacies stocked naloxone.
Vallersnes OM, Persett PS, Øiestad EL, Karinen R, Heyerdahl F, Hovda KE.
Clin Toxicol (Phila). 2017 Apr 13:1-9. doi: 10.1080/15563650.2017.1312002. [Epub ahead of print]
Comment: There are drug fads, but there are core drugs that dominate the scene and tend to stick around.
Weaver L, Palombi L, Bastianelli KM.
J Pharm Pract. 2017 Jan 1:897190017702304. doi: 10.1177/0897190017702304. [Epub ahead of print]
Comment: Information on naloxone formulations for pharmacists.
Horsburgh K, McAuley A.
Drug Alcohol Rev. 2017 Apr 10. doi: 10.1111/dar.12542. [Epub ahead of print]
Comment: Implementation challenges.
Alford DP, Cohen ML, Reynolds EE.
Ann Intern Med. 2017 Apr 4;166(7):506-513. doi: 10.7326/M17-0287.
Comment: Case review for clinicians.
Wakeman SE, Kanter GP, Donelan K.
J Addict Med. 2017 Apr 3. doi: 10.1097/ADM.0000000000000314. [Epub ahead of print]
Comment: Not so long ago, a physician was on their own in treating diabetes.
They had a ton of medications, so the situation was better than for most substance use disorders. But they didn’t have nutritionists and other services to round off care and ensure patients were well taken care of; it was tough and often dissatisfying. Now they have more wraparound services. Do it for substance use disorders and you get a similar improvement in satisfaction all around.
Dumenco L, Monteiro K, Mello M, Collins S, Operario D, Scanlan K, Dollase R, George P.
R I Med J (2013). 2017 Apr 3;100(4):16-18.
Comment: Addressing the Rhode Island crisis.
Rech MA, Barbas B, Chaney W, Greenhalgh E, Turck C.
Ann Emerg Med. 2017 Mar 25. pii: S0196-0644(17)30194-4. doi: 10.1016/j.annemergmed.2017.02.015.
Comment: Naloxone, fentanyl, and midazolam are often used intranasal in emergency settings.
Knudsen HK, Havens JR, Lofwall MR, Studts JL, Walsh SL.
Drug Alcohol Depend. 2017 Apr 1;173 Suppl 1:S55-S64. doi: 10.1016/j.drugalcdep.2016.08.642.
Comment: these ecologic studies are hard to interpret.
Dunn KE, Yepez-Laubach C, Nuzzo PA, Fingerhood M, Kelly A, Berman S, Bigelow GE.
Drug Alcohol Depend. 2017 Apr 1;173 Suppl 1:S39-S47. doi: 10.1016/j.drugalcdep.2016.12.003.
Comment: Interesting data from an online training
Wilson CG, Rodriguez F, Carrington AC, Fagan EB.
J Am Pharm Assoc (2003). 2017 Mar – Apr;57(2S):S130-S134. doi: 10.1016/j.japh.2016.12.076. Epub 2017 Feb 9.
Comment: Chart review identified a large number of patients eligible for naloxone and only about 3% had the medication on their med list.
Faul M, Bohm M, Alexander C.
MMWR Morb Mortal Wkly Rep. 2017 Mar 31;66(12):320-323. doi: 10.15585/mmwr.mm6612a2.
Comment: As we shifted away from methadone for pain, there were fewer methadone deaths. I’m think deck chairs, Titanic …
Weiner SG, Mitchell PM, Temin ES, Langlois BK, Dyer KS.
Prehosp Emerg Care. 2017 May-Jun;21(3):322-326. doi: 10.1080/10903127.2017.1282562. Epub 2017 Feb 6.
Comment: BLS naloxone is a good thing.
Nielsen S, Peacock A, Lintzeris N, Bruno R, Larance B, Degenhardt L.
Pain Med. 2017 Mar 13. doi: 10.1093/pm/pnx021. [Epub ahead of print]
Comment: 14% had experienced overdose symptoms They liked the idea of naloxone but didn’t know much about overdose.
Mack KA, Jones CM, McClure RJ.
Pain Med. 2017 Mar 15. doi: 10.1093/pm/pnx007. [Epub ahead of print]
Comment: Radical shifts in direct dispensing of opioids, particularly in Florida. Wow.
Meacham MC, Roesch SC, Strathdee SA, Lindsay S, Gonzalez-Zuniga P, Gaines TL.
Drug Alcohol Rev. 2017 Mar 24. doi: 10.1111/dar.12524. [Epub ahead of print]
Comment: Polydrug use (and polyroute) and HIV & overdose risk.
Fischer B, Rehm J.
Drug Alcohol Rev. 2017 Mar 23. doi: 10.1111/dar.12539. [Epub ahead of print]
Comment: This is an interesting one. The authors describe the situation well. The interesting part, however, is that they write “little did we know” how bad it was going to get. Well … the piece they refer to was written by them in 2009 (Thinking the unthinkable: could the increasing misuse of prescription opioids among street drug users offer benefits for public health? Public Health. 2009). In that same issue, I wrote a companion piece in which I disagreed with their thesis that overprescribing opioids could be a good thing and emphasized the need to respond to the overdose epidemic (Balancing the costs and benefits of opioid analgesics in the United States. Public Health. 2009). My point is that, certainly by 2009, we did know.
Jones JD, Campbell A, Metz VE, Comer SD.
Addict Behav. 2017 Mar 9;71:104-106. doi: 10.1016/j.addbeh.2017.03.008. [Epub ahead of print]
Comment: The best study to-date demonstrating the lack of risk compensation associated with naloxone provision.
Al-Tayyib A, Koester S, Langegger S, Raville L.
Subst Use Misuse. 2017 Mar 21:1-8. doi: 10.1080/10826084.2016.1271432. [Epub ahead of print]
Comment: Methamphetamine has largely replaced cocaine as the stimulant injected alongside heroin in much of the U.S. There are suggestions that the apparent role of cocaine in contributing to heroin overdose may also apply to methamphetamine.
Abrahamsson T, Berge J, Öjehagen A, Håkansson A.
Drug Alcohol Depend. 2017 Feb 28;174:58-64. doi: 10.1016/j.drugalcdep.2017.01.013. [Epub ahead of print]
Comment: Sedating drugs are associated with mortality in methadone patients. It’s important to ask, however, the mechanism of this. Those in need of these medications may simply be at higher risk of death. In the absence of randomized trial data, it is hard to rule out such a confounder – see paper #16 however, which gets pretty close.
Soc Sci Med. 2017 Mar 9;180:20-27. doi: 10.1016/j.socscimed.2017.03.013. [Epub ahead of print]
Comment: The utilization of the context of drug use as an opportunity for intervention.
Brinkley-Rubinstein L, Cloud DH, Davis C, Zaller N, Delany-Brumsey A, Pope L, Martino S, Bouvier B, Rich J.
Int J Prison Health. 2017 Mar 13;13(1):25-31. doi: 10.1108/IJPH-08-2016-0039.
Byard RW, Kenneally M.
Forensic Sci Med Pathol. 2017 Mar 15. doi: 10.1007/s12024-017-9855-8. [Epub ahead of print]
Comment: Authors suggest that the patient intended to overdose and get admitted to a secure psychiatric facility, with pills stored in the rectum for use while in the facility, but died by accident.
J Psychoactive Drugs. 2017 Mar 15:1-7. doi: 10.1080/02791072.2017.1295334. [Epub ahead of print]
Chwistek M, Wolf M.
J Palliat Med. 2017 Mar 15. doi: 10.1089/jpm.2017.0087. [Epub ahead of print] No abstract available.
Comment: A summary of co-prescribing for palliative care providers.
Srivastava A, Kahan M, Nader M.
Can Fam Physician. 2017 Mar;63(3):200-205. Review.
Comment: Agonist treatment is more effective.
Morton KJ, Harrand B, Floyd CC, Schaefer C, Acosta J, Logan BC, Clark K.
J Am Pharm Assoc (2003). 2017 Mar – Apr;57(2S):S99-S106.e5. doi: 10.1016/j.japh.2017.01.017.
Comment: Great program they describe, but not clear if the claims for naloxone were related to direct provision from pharmacy or an increase in prescriptions from physicians and mid-level providers. Also the increase in provision was co-incident with the availability of the new nasal naloxone that made provision easier.
Oliva EM, Christopher ML, Wells D, Bounthavong M, Harvey M, Himstreet J, Emmendorfer T, Valentino M, Franchi M, Goodman F, Trafton JA; Veterans Health Administration Opioid Overdose Education and Naloxone Distribution National Support and Development Workgroup..
J Am Pharm Assoc (2003). 2017 Mar – Apr;57(2S):S168-S179.e4. doi: 10.1016/j.japh.2017.01.022.
Comment: 39,000 VA patients got naloxone by the end of 2016. Seriously impressive work by those who coordinated the project and the many VA providers.
Duvivier H, Gustafson S, Greutman M, Jangchup T, Harden AK, Reinhard A, Warshany K.
J Am Pharm Assoc (2003). 2017 Mar – Apr;57(2S):S135-S140. doi: 10.1016/j.japh.2017.01.005.
Comment: More on pharmacists and opioid safety/naloxone.
Heavey SC, Burstein G, Moore C, Homish GG.
J Public Health Manag Pract. 2017 Mar 1. doi: 10.1097/PHH.0000000000000538. [Epub ahead of print]
Comment: Can only access abstract, but looks like they did surveys and follow ups for trainees in a naloxone program in Erie County NY. They found that a lot of trainees were family rather than drug users themselves.
Hedegaard H, Warner M, Minino AM.
NCHS Data Brief. 2017 Feb;(273):1-8.
Comment: Deaths from stimulants and all classes of opioids, with the exception of methadone, have been increasing since 2010.
Barry T, Klimas J, Tobin H, Egan M, Bury G.
Br J Gen Pract. 2017 Apr;67(657):e267-e273. doi: 10.3399/bjgp17X689857. Epub 2017 Feb 28.
Comment: In Ireland, 75% of general practitioners had patients who used illicit opioids, 25% provided methadone treatment, and two-thirds supported increased access to naloxone.
Bhatraju EP, Grossman E, Tofighi B, McNeely J, DiRocco D, Flannery M, Garment A, Goldfeld K, Gourevitch MN, Lee JD.
Addict Sci Clin Pract. 2017 Feb 28;12(1):7. doi: 10.1186/s13722-017-0072-2.
Comment: Home inductions with buprenorphine lead to similar outcomes as in-clinic efforts. This is a big deal as in-clinic inductions are a barrier to broadening the base of providers willing to address the – largely iatrogenic – opioid epidemic.
Pavarin RM, Fioritti A, Sanchini S.
J Subst Abuse Treat. 2017 Feb 23. pii: S0740-5472(16)30376-2. doi: 10.1016/j.jsat.2017.02.009. [Epub ahead of print]
Comment: HIV, overdose, and liver disease. The age range in which heroin users die at the most increased rate relative to the general population is 25-34 years.
Devries J, Rafie S, Polston G.
J Am Pharm Assoc (2003). 2017 Mar – Apr;57(2S):S154-S160. doi: 10.1016/j.japh.2017.01.002. Epub 2017 Feb 21.
Comment: UC San Diego, implemented electronic health record alert, saw an increase from 4.5 to 46 naloxone prescriptions per month.
Finkelstein Y, Macdonald EM, Gonzalez A, Sivilotti ML, Mamdani MM, Juurlink DN; Canadian DrugSafety And Effectiveness Research Network (CDSERN)..
Pediatrics. 2017 Mar;139(3). pii: e20162887. doi: 10.1542/peds.2016-2887. Epub 2017 Feb 20.
Comment: If you have opioids in the house, you should have naloxone there too.
Rolland B, Bouhassira D, Authier N, Auriacombe M, Martinez V, Polomeni P, Brousse G, Schwan R, Lack P, Bachellier J, Rostaing S, Bendimerad P, Vergne-Salle P, Dematteis M, Perrot S.
Rev Med Interne. 2017 Feb 14. pii: S0248-8663(17)30021-8. doi: 10.1016/j.revmed.2016.12.024. [Epub ahead of print] French.
Comment: Just as complicated in French as in English.
Akers JL, Hansen RN, Oftebro RD.
J Am Pharm Assoc (2003). 2017 Mar – Apr;57(2S):S161-S167. doi: 10.1016/j.japh.2017.01.006. Epub 2017 Feb 13.
Comment: Process outcomes.
Hsu DJ, McCarthy EP, Stevens JP, Mukamal KJ.
Addiction. 2017 Feb 13. doi: 10.1111/add.13795. [Epub ahead of print]
Penm J, MacKinnon NJ, Boone JM, Ciaccia A, McNamee C, Winstanley EL.
J Am Pharm Assoc (2003). 2017 Mar – Apr;57(2S):S148-S153. doi: 10.1016/j.japh.2017.01.001. Epub 2017 Feb 8.
Shafer E, Bergeron N, Smith-Ray R, Robson C, O’Koren R.
J Am Pharm Assoc (2003). 2017 Mar – Apr;57(2S):S123-S129. doi: 10.1016/j.japh.2016.12.075. Epub 2017 Feb 3.
Comment: Drug disposal, naloxone, patient education.
Rudd-Barnard G, Pangarkar S, Moaleji N, Glassman P.
J Pain. 2016 Apr;17(4S):S11. doi: 10.1016/j.jpain.2016.01.044. Epub 2016 Mar 24. No abstract available.
Comment: Some largely inpatient data on naloxone use.
Palmer E, Hart S, Freeman PR.
J Am Pharm Assoc (2003). 2017 Mar – Apr;57(2S):S118-S122. doi: 10.1016/j.japh.2016.12.071. Epub 2017 Feb 1.
Comment: Increased number of pharmacists that have gotten certified to dispense naloxone under a physician protocol.
Marsden J, Stillwell G, Jones H, Cooper A, Eastwood B, Farrell M, Lowden T, Maddalena N, Metcalfe C, Shaw J, Hickman M.
Addiction. 2017 Feb 4. doi: 10.1111/add.13779. [Epub ahead of print]
Comment: Wow! Prison agonist treatment was associated with 75% reduction in all-cause death and 85% reduction in drug overdose death in the first month out of prison.
Monteiro K, Dumenco L, Collins S, Bratberg J, MacDonnell C, Jacobson A, Dollase R, George P.
J Am Pharm Assoc (2003). 2017 Mar – Apr;57(2S):S113-S117. doi: 10.1016/j.japh.2016.12.069. Epub 2017 Jan 31.
Comment: I’ve always felt that health professionals respond better to any disease where they learn interventions to treat it.
Willman MW, Liss DB, Schwarz ES, Mullins ME.
Clin Toxicol (Phila). 2017 Feb;55(2):81-87. doi: 10.1080/15563650.2016.1253846. Epub 2016 Nov 16. Review.
Willman MW, Liss DB, Schwarz ES, Mullins ME.
Clin Toxicol (Phila). 2017 Apr;55(4):309-310. doi: 10.1080/15563650.2017.1284337. Epub 2017 Feb 3. No abstract available.
Comment: Authors defend their conclusion that people who respond to naloxone given for presumed heroin overdose can safely refuse transport if there is no sign of returning opioid toxicity after an hour.
J Psychosoc Nurs Ment Health Serv. 2017 Jan 1;55(1):18-23. doi: 10.3928/02793695-20170119-03.\
Comment: Medications to treat opioid use disorder.
Li AT, Chu FK.
Clin Toxicol (Phila). 2017 Mar;55(3):233. doi: 10.1080/15563650.2016.1277236. Epub 2017 Jan 24. No abstract available.
Comment: Fascinating. I love these case reports.
Isbister GK, Heppell SP, Page CB, Ryan NM.
Clin Toxicol (Phila). 2017 Mar;55(3):187-192. doi: 10.1080/15563650.2016.1277234. Epub 2017 Jan 20.
Comment: Again, case reports are fascinating.
Monheit B, Pietrzak D, Hocking S.
Aust Fam Physician. 2016 Dec;45(12):862-866.
Comment: Review for Australian physicians.
Leece P, Gassanov M, Hopkins S, Marshall C, Millson P, Shahin R.
Can J Public Health. 2016 Oct 20;107(3):e224-e230. doi: 10.17269/cjph.107.5480.
Comment: Process outcomes.
Rowe C, Vittinghoff E, Santos GM, Behar E, Turner C, Coffin PO.
Acad Emerg Med. 2017 Apr;24(4):475-483. doi: 10.1111/acem.13121. Epub 2017 Mar 17.
Comment: ICD codes for opioid poisoning only identified 25% of opioid overdose events identified by clinical chart review, and naloxone administration didn’t help to refine that. Such a bummer that DAWN isn’t around anymore, because we just can’t get good enough substance use-related data from coding / big data – we need manual reviews.
Toce MS, Burns MM, O’Donnell KA.
Clin Toxicol (Phila). 2017 Jan;55(1):12-17. doi: 10.1080/15563650.2016.1244337. Epub 2016 Oct 19.
Comment: Most develop signs of toxicity within 8 hours of exposure.
J Addict Dis. 2016 Oct-Dec;35(4):339-345. No abstract available.
Comment: Can’t access.
Donroe JH, Holt SR, Tetrault JM.
CMAJ. 2016 Dec 6;188(17-18):1232-1239. Epub 2016 Sep 19. Review. No abstract available.
Comment: We have treatments! Use them.
BMJ. 2016 Sep 14;354:i4930. doi: 10.1136/bmj.i4930. No abstract available.
Comment: Focus on public health.
Mitchell KD, Higgins LJ.
J Addict Nurs. 2016 Jul-Sep;27(3):160-79. doi: 10.1097/JAN.0000000000000132. Review.
Comment: Can’t access.
Jones MJ, Hernandez BS, Janis GC, Stellpflug SJ.
Clin Toxicol (Phila). 2017 Jan;55(1):55-59. doi: 10.1080/15563650.2016.1209767. Epub 2016 Aug 23. Erratum in: Clin Toxicol (Phila). 2017 Jan;55(1):76.
Comment: Responded to naloxone in the field.
DiPrinzio D, Sethi R.
Prim Care Companion CNS Disord. 2016 Apr 7;18(2). doi: 10.4088/PCC.15l01871. eCollection 2016. No abstract available.
Comment: Authors argue that methadone used in opioid use disorder treatment should show up in prescription drug monitoring programs. As an individual clinician, that would be helpful for me. However, the stigma around opioid use disorder treatment is still massive.
Zhang XC, Siket M, Binder W.
R I Med J (2013). 2016 Jul 1;99(7):29-31. No abstract available.
Comment: Can’t access.
Sharma B, Bruner A, Barnett G, Fishman M.
Child Adolesc Psychiatr Clin N Am. 2016 Jul;25(3):473-87. doi: 10.1016/j.chc.2016.03.002. Epub 2016 Apr 9. Review.
Comment: A review.
Lembke A, Humphreys K, Newmark J.
Am Fam Physician. 2016 Jun 15;93(12):982-90.
Comment: Again, this is so complicated.
Tjagvad C, Skurtveit S, Linnet K, Andersen LV, Christoffersen DJ, Clausen T.
Eur Addict Res. 2016;22(5):249-58. doi: 10.1159/000446429. Epub 2016 Jun 1.
Comment: This is difficult to tease out, as liberal methadone can reach the highest risk persons, who would also have a higher risk of death.
Moore PQ, Weber J, Cina S, Aks S.
Am J Emerg Med. 2017 May 8. pii: S0735-6757(17)30367-4. doi: 10.1016/j.ajem.2017.05.003. [Epub ahead of print]
Comment: Other studies have found these data to have real limitations, but in general they should pick up on large trends. The other issue is that lay naloxone responders may not call EMS after a successful reversal, so a community with excellent naloxone coverage may not experience EMS upticks in the context of a small outbreak.
Somerville NJ, O’Donnell J, Gladden RM, Zibbell JE, Green TC, Younkin M, Ruiz S, Babakhanlou-Chase H, Chan M, Callis BP, Kuramoto-Crawford J, Nields HM, Walley AY.
MMWR Morb Mortal Wkly Rep. 2017 Apr 14;66(14):382-386. doi: 10.15585/mmwr.mm6614a2.
Comment: Just read it. It’s too important to summarize.
Bode AD, Singh M, Andrews J, Kapur GD, Baez AA.
Am J Emerg Med. 2017 Feb 28. pii: S0735-6757(17)30158-4. doi: 10.1016/j.ajem.2017.02.043. [Epub ahead of print] No abstract available.
Comment: Authors report increased opioid overdose and a greater increase in naloxone, arguing that this means the increase was likely driven by fentanyl. I’m not sure I buy this analysis, in part because of some basic math errors (e.g. “The greatest increase in OOD was observed during the month of September with 65 cases in 2015 and 266 cases in 2016 (182% [sic – should read 326%]) (Fig. 1a/Table 1). The number of naloxone vials used from July–September rose from 212 in 2015 to 1221 in 2016, a 476% increase (Table 2a).” The analysis also doesn’t account for the number of naloxone doses actually used on individual cases (not all naloxone administrations are coded as overdose events).
Mercado MC, Sumner SA, Spelke MB, Bohm MK, Sugerman DE, Stanley C.
Pain Med. 2017 Mar 6. doi: 10.1093/pm/pnx015. [Epub ahead of print]
Frank RG, Pollack HA.
N Engl J Med. 2017 Feb 16;376(7):605-607. doi: 10.1056/NEJMp1615145. No abstract available.
Comment: Nope, still don’t like street use of fentanyl.
Krause D, Plörer D, Koller G, Martin G, Winter C, Adam R, Canolli M, Al-Iassin J, Musselmann R, Walcher S, Schäfer F, Pogarell O.
Subst Use Misuse. 2017 Apr 16;52(5):639-645. doi: 10.1080/10826084.2016.1246571. Epub 2017 Feb 3.
Comment: Interesting – high rates of fentanyl use in a population of users in Munich, Germany.
Tomassoni AJ, Hawk KF, Jubanyik K, Nogee DP, Durant T, Lynch KL, Patel R, Dinh D, Ulrich A, D’Onofrio G.
MMWR Morb Mortal Wkly Rep. 2017 Feb 3;66(4):107-111. doi: 10.15585/mm6604a4.
Comment: Again, just read it.
Lee D, Chronister CW, Broussard WA, Utley-Bobak SR, Schultz DL, Vega RS, Goldberger BA.
J Anal Toxicol. 2016 Oct;40(8):588-594.
Comment: Lots of it.
105) Fentanyl misuse.
Ruzycki S, Yarema M.
CMAJ. 2016 Jun 14;188(9):673. doi: 10.1503/cmaj.151378. Epub 2016 Apr 18. No abstract available.
Comment: Brief overview.
Irwin A, Jozaghi E, Weir BW, Allen ST, Lindsay A, Sherman SG.
Harm Reduct J. 2017 May 12;14(1):29. doi: 10.1186/s12954-017-0153-2.
Comment: The data support these facilities as an important element of the overdose response.
Bouvier BA, Elston B, Hadland SE, Green TC, Marshall BD.
Harm Reduct J. 2017 Feb 20;14(1):13. doi: 10.1186/s12954-017-0139-0.
Comment: The opioid users who could most benfit from an injection facility are the most likely to want to use an injection facility.
N Engl J Med. 2017 Mar 16;376(11):1011-1013. doi: 10.1056/NEJMp1613651. No abstract available.
Comment: See title.